Core Viewpoint - The company reported a strong recovery in overseas demand, leading to a return to growth in performance, with significant contributions from both international and domestic markets [2]. Financial Performance - For the first half of 2025, the company achieved revenue of 266 million yuan, representing a year-on-year increase of 20.50%, and a net profit attributable to shareholders of 74 million yuan, up by 5.52% [1]. - In Q2 2025, revenue was 119 million yuan, reflecting a growth of 15.52%, while net profit attributable to shareholders decreased by 13.55% to 28 million yuan [1]. Business Segmentation - Revenue from medical endoscope instruments reached 207 million yuan, a year-on-year increase of 17.72%, accounting for 78.28% of main business revenue [2]. - Optical product revenue was 57 million yuan, growing by 34.62%, making up 21.72% of main business revenue [2]. Market Dynamics - The overseas market emerged as the main growth driver, with revenue increasing by approximately 28.6% year-on-year, while domestic market revenue showed stable growth [2]. - The slower profit growth compared to revenue is attributed to increased investments in R&D, domestic marketing networks, and overseas factory setups, along with reduced foreign exchange and investment income [2]. Global Expansion Strategy - The company's proactive global production layout has effectively mitigated trade risks, with a factory in Thailand now producing endoscopes and light source modules primarily for the U.S. market [2]. - The second phase of production line construction in Thailand has been initiated, which will include complete assembly and GMP production workshops, laying the groundwork for future capacity expansion [2]. Product Development and Partnerships - The company is deepening cooperation with major U.S. clients, having officially launched the development of the next-generation endoscope system, with several products entering trial production [3]. - In the domestic market, the company continues to expand its product line, obtaining registration for new surgical instruments and initiating collaborations in new business areas [3]. Investment Outlook - The company maintains its profit forecast, expecting net profits attributable to shareholders of 180 million, 230 million, and 280 million yuan for 2025-2027, representing year-on-year growth rates of 35.2%, 24.6%, and 22.8% respectively [3]. - The estimated EPS for the same period is projected to be 1.53, 1.90, and 2.34 yuan, with corresponding PE ratios of 31, 25, and 20 times [3].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to achieve significant growth in 2024, with revenue projected at 2.836 billion yuan (up 59.8% year-on-year) and net profit attributable to shareholders at 733 million yuan (up 55.3%) [5] - The company benefits from strong customer relationships and robust manufacturing capabilities, which contribute to impressive revenue and profit growth [5] - The company has adjusted its profit forecasts for 2025-2026 due to increased capital expenditures related to capacity expansion, with net profit estimates of 864 million yuan for 2025 and 1.049 billion yuan for 2026 [5] Revenue Summary - The primary revenue source for the company remains stainless steel vacuum containers, with revenue from stainless steel vacuum cups reaching 2.682 billion yuan (up 57.64%) in 2024, accounting for 94.56% of total revenue [6] - International market revenue has been a significant growth driver, with overseas revenue at 2.690 billion yuan (up 59.39%), representing 94.85% of total revenue [6] Profitability Summary - The company's gross margin for 2024 is reported at 37.67% (down 3.05 percentage points), with a quarterly gross margin of 33.3% in Q4 2024 (down 10.5 percentage points) [7] - The net profit margin for 2024 is 25.8% (down 0.7 percentage points), with a quarterly net profit margin of 23.7% in Q4 2024 (down 5.2 percentage points) [7] Company Highlights - The completion of the Vietnam production capacity project, which can produce 13.5 million stainless steel vacuum cups annually, enhances the company's order capacity and competitive advantage [8] - The company has deepened its partnership with PMI, with revenue from this client reaching 2.470 billion yuan (up 63.96%), accounting for 87.15% of total revenue [8] Financial Summary and Valuation Metrics - The company’s revenue is projected to grow from 2.836 billion yuan in 2024 to 5.144 billion yuan in 2027, with a compound annual growth rate of approximately 19.9% [9] - The estimated earnings per share (EPS) for 2025, 2026, and 2027 are 8.32 yuan, 10.10 yuan, and 12.24 yuan, respectively [9]